We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite Boston Scientific’s contention that the multiple recalls of its Taxus drug-eluting stent have had little effect on the firm’s financial situation, the company warned Wall Street analysts last week that it might fall short of its third- and fourth-quarter earnings projections.
In a move that has drawn sharp criticism from patient advocates, Pfizer last week decided to drop its own drug discount card for the elderly and shift participants to a new Medicare-approved card.
West Virginia lawmakers this month will consider adopting Australia’s method of determining drug prices — a move that could reward drugmakers for offering innovative products while forcing firms to provide the lowest price on products that offer few new benefits.
As the FDA prepares to hold its first discussion on the scientific issues surrounding follow-on biologics this month, European health officials are preparing a guidance that will let generic firms seek approval for biosimilar products as soon as next fall.
Pfizer has dropped its drug discount card for the elderly and is shifting participants to a new Medicare-approved discount card — a move that has drawn sharp criticism from patient advocates.
The Centers for Medicare & Medicaid Services (CMS) has contracted with IntegriGuard to provide oversight of the sponsors of the Medicare prescription drug card program.
Under new formulary guidelines that favor lower-cost brands and generic products, the U.S. Air Force no longer will dispense some widely used, but expensive, brand pharmaceutical products.
A clinical research group says that to reduce costs and delays in the drug development process, the FDA should consider fundamentally redesigning the current clinical trial model, including allowing investigational drugs to go to market on a conditional basis.
According to at least one pharmaceutical analyst, the U.S. Pharmacopeia’s (USP’s) proposed guidelines for developing Medicare drug formularies could make it difficult for some brand products to make the cut.
A new study shows that the recently proposed guidelines for developing Medicare drug formularies by the U.S. Pharmacopeia (USP) may not provide enough drug choices for some patients